Sarah S Donaldson

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG
    S S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 5302, USA
    Int J Radiat Oncol Biol Phys 51:718-28. 2001
  2. ncbi request reprint Ewing sarcoma: radiation dose and target volume
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5847, USA
    Pediatr Blood Cancer 42:471-6. 2004
  3. ncbi request reprint Advances toward an understanding of brainstem gliomas
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 24:1266-72. 2006
  4. ncbi request reprint VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial
    Sarah S Donaldson
    Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 20:3081-7. 2002
  5. ncbi request reprint Subspecialty training and certification for radiation oncology
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305 5302, USA
    J Am Coll Radiol 1:488-92. 2004
  6. ncbi request reprint Pediatric Hodgkin's disease--up, up, and beyond
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, 300 Pasteur Drive, Rm A083, Stanford, CA 94305 5302, USA
    Int J Radiat Oncol Biol Phys 54:1-8. 2002
  7. ncbi request reprint A discourse: the 2002 Wataru W. Sutow lecture. Hodgkin disease in children--perspectives and progress
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5302, USA
    Med Pediatr Oncol 40:73-81. 2003
  8. pmc Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group
    A Yuriko Minn
    Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 28:4228-32. 2010
  9. ncbi request reprint Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease
    Sarah S Donaldson
    Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 25:332-7. 2007
  10. ncbi request reprint Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group
    Torunn I Yock
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 24:3838-43. 2006

Detail Information

Publications49

  1. ncbi request reprint Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG
    S S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 5302, USA
    Int J Radiat Oncol Biol Phys 51:718-28. 2001
    ..To evaluate the outcome and toxicity of hyperfractionated radiotherapy (HFRT) vs. conventionally fractionated radiotherapy (CFRT) in children with Group III rhabdomyosarcoma (RMS)...
  2. ncbi request reprint Ewing sarcoma: radiation dose and target volume
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5847, USA
    Pediatr Blood Cancer 42:471-6. 2004
    ..However, the preferred assessment following radiation therapy is local control...
  3. ncbi request reprint Advances toward an understanding of brainstem gliomas
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 24:1266-72. 2006
    ..Although we briefly discuss the nondiffuse tumors, we focus specifically on those diffuse brainstem tumors that regrettably still carry a bleak prognosis...
  4. ncbi request reprint VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial
    Sarah S Donaldson
    Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 20:3081-7. 2002
    ..To evaluate outcome and assess toxicity of children and adolescents with early-stage, favorable Hodgkin's disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) and low-dose, involved-field radiation...
  5. ncbi request reprint Subspecialty training and certification for radiation oncology
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305 5302, USA
    J Am Coll Radiol 1:488-92. 2004
    ..As a result, the authors believe that subspecialty training and certification in radiation oncology is not a near-term possibility...
  6. ncbi request reprint Pediatric Hodgkin's disease--up, up, and beyond
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, 300 Pasteur Drive, Rm A083, Stanford, CA 94305 5302, USA
    Int J Radiat Oncol Biol Phys 54:1-8. 2002
    ..The universal goal of cure without late effects is realistic for almost all children with Hodgkin's disease today...
  7. ncbi request reprint A discourse: the 2002 Wataru W. Sutow lecture. Hodgkin disease in children--perspectives and progress
    Sarah S Donaldson
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5302, USA
    Med Pediatr Oncol 40:73-81. 2003
    ..This approach is now universal. Today, the 5-year relative survival rate for American children with Hodgkin disease, who are under 14 years of age, is 94%, a dramatic and remarkable achievement...
  8. pmc Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group
    A Yuriko Minn
    Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 28:4228-32. 2010
    ..The goal of this study was to determine the frequency and clinical features of early treatment failure during induction chemotherapy before protocol radiation therapy for children with intermediate-risk rhabdomyosarcoma (RMS)...
  9. ncbi request reprint Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease
    Sarah S Donaldson
    Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 25:332-7. 2007
    ....
  10. ncbi request reprint Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group
    Torunn I Yock
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 24:3838-43. 2006
    ..We investigated the relationship between the type of local control modality, surgery, radiation (RT) or both (S + RT), and subsequent risk for local failure (LF) in patients with nonmetastatic pelvic Ewing sarcoma treated on INT-0091...
  11. pmc Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group
    Trang H La
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Int J Radiat Oncol Biol Phys 80:1151-7. 2011
    ..To evaluate the incidence and prognostic factors for regional failure, with attention to the in-transit pathways of spread, in children with nonmetastatic rhabdomyosarcoma of the extremity...
  12. ncbi request reprint Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study
    Moody D Wharam
    Children s Oncology Group, Arvadia, CA, USA
    J Clin Oncol 22:1902-8. 2004
    ....
  13. pmc Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group
    Leo Mascarenhas
    Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    J Clin Oncol 28:4658-63. 2010
    ..To compare response rates for two schedules of irinotecan with vincristine in patients with rhabdomyosarcoma at first relapse or disease progression...
  14. pmc Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group
    Chi Lin
    Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA
    Int J Radiat Oncol Biol Phys 82:1764-70. 2012
    ....
  15. ncbi request reprint Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy
    Ron S Smith
    Department of Radiation Oncology, Stanford University School of Medicine, CA, USA
    J Clin Oncol 21:2026-33. 2003
    ..Evaluation of pretreatment factors to identify children at high risk for relapse after combined-modality therapy for Hodgkin's disease...
  16. doi request reprint Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group
    Lynn Million
    Department of Radiation Oncology, University of Utah Health Sciences and Huntsman Cancer Institute, Salt Lake City, UT, USA
    Int J Radiat Oncol Biol Phys 80:333-8. 2011
    ..We reviewed operative bed recurrences to determine if noncompliance with RT protocol guidelines influenced local-regional control...
  17. pmc Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group
    Trang H La
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Int J Radiat Oncol Biol Phys 80:206-12. 2011
    ..To evaluate the outcome of children with rhabdomyosarcoma (RMS) of the hand or foot treated with surgery and/or local radiotherapy (RT)...
  18. ncbi request reprint High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices
    YeeYie E Lieskovsky
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 5847, USA
    J Clin Oncol 22:4532-40. 2004
    ..To evaluate the outcome of pediatric patients with refractory or relapsed Hodgkin's disease (HD) who undergo high-dose therapy and autologous hematopoietic stem-cell transplantation (AHSCT)...
  19. ncbi request reprint Controversies in radiotherapy for pediatric Hodgkin's lymphoma
    Ellen A Wiegner
    Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Rev Anticancer Ther 11:1357-66. 2011
    ..Response-adapted therapy is emerging as a promising strategy to attenuate therapy and thereby reduce toxicity in children with an excellent prognosis and intensify therapy in those children at higher risk of progression or relapse...
  20. doi request reprint Changes in health status among aging survivors of pediatric upper and lower extremity sarcoma: a report from the childhood cancer survivor study
    Neyssa Marina
    Department of Pediatrics, Stanford University and Lucile Packard Children s Hospital, Palo Alto, CA, USA
    Arch Phys Med Rehabil 94:1062-73. 2013
    ..To evaluate health status and participation restrictions in survivors of childhood extremity sarcomas...
  21. ncbi request reprint Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy
    Christopher C Dvorak
    Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, Stanford University School of Medicine, Palo Alto, California 94304, USA
    Pediatr Blood Cancer 48:582-5. 2007
    ..These cases demonstrate that there is a role for ATRA plus differentiating chemotherapy other than arsenic trioxide in the treatment of relapsed APML...
  22. ncbi request reprint Profile of daily life in children with brain tumors: an assessment of health-related quality of life
    Sundeep R Bhat
    Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA
    J Clin Oncol 23:5493-500. 2005
    ..We aimed to show that universal assessment of HRQOL could be obtained easily by using the PedsQL 4.0 and to provide a composite profile of their daily lives...
  23. ncbi request reprint Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV
    Jeff M Michalski
    Department of Radiation Oncology, Washington University School of Medicine, Box 8224, 4921 Parkview Place, Lower Level, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 59:1027-38. 2004
    ....
  24. doi request reprint Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma
    Carolina E Fasola
    Department of Radiation Oncology, Stanford University, Stanford, California, USA
    Int J Radiat Oncol Biol Phys 86:930-5. 2013
    ..The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa...
  25. ncbi request reprint Radiation therapy for intracranial germ cell tumors
    Daphne A Haas-Kogan
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 56:511-8. 2003
    ....
  26. doi request reprint Treatment of pediatric hodgkin lymphoma
    Michael R Olson
    Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305 5847, USA
    Curr Treat Options Oncol 9:81-94. 2008
    ..The majority of children failing combined-modality treatment undergo high-dose chemotherapy followed by autologous hematopoietic stem cell rescue, oftentimes with consolidative radiotherapy...
  27. pmc Resectable pediatric nonrhabdomyosarcoma soft tissue sarcoma: which patients benefit from adjuvant radiation therapy and how much?
    Lynn Million
    Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    ISRN Oncol 2012:341408. 2012
    ..This paper reviews the sparse literature from clinical trials and retrospective studies of resected pediatric NRSTS to discern local recurrence rates in relationship to the use of radiation therapy...
  28. ncbi request reprint Primary radiotherapy for localized orbital MALT lymphoma
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305, USA
    Int J Radiat Oncol Biol Phys 52:657-63. 2002
    ..To define the natural history, prognosis, and radiocurability of localized orbital extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)...
  29. ncbi request reprint Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone
    Holcombe E Grier
    Department of Pediatric Hematology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    N Engl J Med 348:694-701. 2003
    ..We designed a study to test whether the addition of these drugs to a standard regimen would improve the survival of patients with newly diagnosed disease...
  30. ncbi request reprint Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group
    Alberto S Pappo
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 25:362-9. 2007
    ....
  31. ncbi request reprint Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation
    Alison M Friedmann
    Pediatric Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 20:3088-94. 2002
    ....
  32. ncbi request reprint Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study
    James S Miser
    City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    J Clin Oncol 22:2873-6. 2004
    ....
  33. ncbi request reprint Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997
    Richard Beverly Raney
    Department of Clinical Pediatrics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Med Pediatr Oncol 38:22-32. 2002
    ..We reviewed 611 patients with parameningeal sarcoma entered on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-II through IV (1978-1997), to delineate treatment results and evaluate prognostic factors...
  34. ncbi request reprint Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study
    Daniel C Bowers
    Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9063, USA
    J Clin Oncol 23:6508-15. 2005
    ..The objectives of this report are to examine the incidence of and risk factors for stroke among childhood Hodgkin's disease (HD) survivors...
  35. ncbi request reprint Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group
    Sheri L Spunt
    St Jude Children s Research Hospital and University of Tennessee College of Medicine, Memphis, Tennessee 38105 2794, USA
    Clin Cancer Res 10:6072-9. 2004
    ..More than half of pediatric rhabdomyosarcoma cases have intermediate-risk features and suboptimal outcome (3-year failure-free survival estimates, 55 to 76%). Dose intensification of known active agents may improve outcome...
  36. ncbi request reprint Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease
    Melissa M Hudson
    Department of Hematology Oncology, Radiological Sciences and Biostatistics, St Jude Children s Research Hospital and the University of Tennessee College of Medicine, Memphis, TN 38105, USA
    J Clin Oncol 22:4541-50. 2004
    ....
  37. doi request reprint Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group
    Beverly Raney
    Children s Cancer Hospital, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Pediatr Blood Cancer 51:17-22. 2008
    ..Determine outcome of patients with cranial parameningeal sarcoma and concurrent metastases treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV...
  38. ncbi request reprint Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV
    John C Breneman
    Children s Hospital Medical Center, Division of Radiation Oncology, Cincinnati, OH 45219 0757, USA
    J Clin Oncol 21:78-84. 2003
    ..To identify risk factors associated with outcomes in children with metastatic rhabdomyosarcoma (RMS) treated on the fourth Intergroup Rhabdomyosarcoma Study (IRS-IV)...
  39. ncbi request reprint Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV
    Alberto S Pappo
    Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada
    J Clin Oncol 21:638-45. 2003
    ..The characteristics and clinical outcomes of children and adolescents with localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma (RMS) treated on national protocols from the Intergroup Rhabdomyosarcoma Group are reported...
  40. doi request reprint Understanding the risk of second malignant tumors in children with Hodgkin's disease
    Sarah S Donaldson
    Int J Radiat Oncol Biol Phys 72:4-5. 2008
  41. ncbi request reprint Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
    Lillian Sung
    The Division of Hematology Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, Ont, M5G 1X8, Canada
    Eur J Cancer 40:1878-85. 2004
    ..Late events after successful treatment for rhabdomyosarcoma occur in 9%. Those with advanced disease and large primary tumours have the highest risk of late events...
  42. ncbi request reprint Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers
    Cécile M Ronckers
    Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland
    Radiat Res 166:618-28. 2006
    ..In summary, we applied models derived from radiobiology to describe the radiation dose-response curve for thyroid cancer in an epidemiological study and found convincing evidence for a downturn in risk at high doses...
  43. ncbi request reprint New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study
    Joseph P Neglia
    Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN, USA
    J Natl Cancer Inst 98:1528-37. 2006
    ..However, the details of the dose-response relationships, the expression of excess risk over time, and the modifying effects of other host and treatment factors have not been well defined...
  44. ncbi request reprint Genetic effects of radiotherapy for childhood cancer: gonadal dose reconstruction
    Marilyn Stovall
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 60:542-52. 2004
    ....
  45. ncbi request reprint Continuing medical education in radiology: a glimpse of the present and of what lies ahead
    Lawrence P Davis
    Department of Radiology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA
    J Am Coll Radiol 2:338-43. 2005
    ..The ACR supports the radiology and radiation oncology community in their efforts at lifelong learning and is developing new and innovative educational programs and tools to accomplish this goal...
  46. ncbi request reprint Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group
    James S Miser
    Division of Pediatrics, Department of Pediatric Hematology Oncology, City of Hope National Medical Center, Duarte, California 91010, USA
    Pediatr Blood Cancer 49:894-900. 2007
    ..We evaluated whether a dose-intensity chemotherapy regimen improved survival for patients with ESFTs of bone with metastases at diagnosis...
  47. pmc Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
    Elizabeth C Bluhm
    Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, MSC 7238, Rockville, MD 20892 7238, USA
    Blood 111:4014-21. 2008
    ..1), mediastinal NHL disease (RR = 5.2), and breast irradiation (RR = 4.3). Survivors of childhood NHL, particularly those treated with chest RT, are at continued increased risk of early mortality and solid tumor SMNs...
  48. ncbi request reprint Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997
    R Beverly Raney
    Department of Clinical Pediatrics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Pediatr Blood Cancer 42:618-25. 2004
    ..We reviewed 56 IRS-IV patients with localized rhabdomyosarcoma [RMS] of the retroperitoneum/pelvis to assess outcome and prognostic factors, including the value of initially excising >or=50% of the tumor (debulking) before chemotherapy...
  49. ncbi request reprint Rhabdomyosarcoma: many similarities, a few philosophical differences
    Sarah S Donaldson
    J Clin Oncol 23:2586-7. 2005